Dengue Vaccine
Japanese drug firm Takeda and Hyderabad-based firm Biological E Ltd tied hands to manufacture their own dengue vaccine. The news was communicated by Takeda in an official statement. The partnership is a very crucial step in the fight against the global public health threat of dengue fever. This also aligns with the disease-specific target, which was set by the World Health Organization (WHO).
This step was taken by the global organization to achieve zero case-fatality rate due to dengue by 2030, Takeda mentioned the same in their statement. They also said that this crucial partnership will substantially enhance manufacturing capabilities, and this will ensure a sustainable global supply of the vaccine.
This co-operation will help Biological E scale up its production capacity to reach over 50 million doses annually. This will also accelerate Takeda’s efforts to increase their manufacturing to a 100 million doses per year within the decade. Takeda Global Vaccine Business Unit President, Gary Dubin said, “We are proud to announce a strategic manufacturing partnership with Biological E Ltd.
The firm has deep expertise in vaccine manufacturing and longstanding support of public health programs around the world. Together, we will combat the dengue on a global scale. We can significantly increase manufacturing capacity for the multi-dose vials of TAK-003 vaccine. This will surely drive sustainable access in more endemic countries.”
As per experts, over half of the world’s population is at dengue risk. This is the fastest-spreading mosquito-borne viral disease at present. 1.3 billion people live in dengue-endemic areas of In India and Southeast Asia.
Thailand, India, and Indonesia are among some of the most highly endemic countries for dengue fever. Telangana CM Anumula Revanth Reddy announced the partnership on Tuesday. He also said that Hyderabad will host the facility where the dengue vaccine will be manufactured.
